15 results about "Human papillomavirus types" patented technology

The first object of the invention is primer sets for amplifying the nucleotide sequence of the L2 gene of human papillomavirus type 16 or L1 gene of human papillomavirus type 18. The second object of the invention is a method for detecting HPV16 or HPV18 viruses. Another object of the invention is a method of detecting HPV16 and HPV18 infections. A fourth object of the invention is a kit for detecting HPV16 or HPV18 infections.

The present invention describes a method of treating a high level of squamous intraepithelial lesion (HSIL) associated with human papilloma virus (HPV) type 16 or HPV type 18 of the cervix. The described methods include assessing the presence or absence of miRNA and isomiRs thereof in one or more biological samples.

Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and / or treating infection with human papillomavirus type 6 and / or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof.[In the formula, R1, R2, p, L1 and L2 are as defined in the specification.]

The present invention provides a monoclonal antibody that specifically recognizes the L1 protein (HPV11 L1) and / or VLP (HPV11 VLP) of human papillomavirus type 11. The specific monoclonal antibody provided by the present invention has no significant cross-reactivity with the L1 proteins and / or VLPs of eight other HPV types (HPV6, 16, 18, 31, 33, 45, 52, and 58), and exhibits high specificity, sensitivity, accuracy, and safety. It can be used to accurately detect the bioactive content of HPV11 L1 protein and / or VLP in vaccine strains and is expected to be widely used in clinical testing and vaccine production.

The application discloses a recombinant protein of human papillomavirus type 52 L1 protein, and the amino acid sequence of the recombinant protein is the amino acid sequence of human papillomavirus type 52 L1 protein (1-141) with a His tag at the N terminal, wherein the amino acid sequence of human papillomavirus type 52 L1 protein (1-141) is shown as SEQ ID NO:1; the recombinant protein is applied to preparation of a reagent for detecting human papillomavirus type 52 infection, and can be used for detecting whether HPV52 antibodies exist in a vaginal washing liquid of a to-be-detected person; the method has the characteristics of high sensitivity and specificity, wide application, and is not dependent on large equipment, and has strong universality.

The invention provides a therapeutic HPV (human papillomavirus) nucleic acid vaccine. The therapeutic HPV nucleic acid vaccine comprises (i) a nucleic acid sequence for encoding an antigen; (ii) a nucleic acid sequence encoding a linker; the linker is selected from at least one of 2A self-cleavage peptide or GS-linked polypeptide; the antigens are early regulatory proteins E6 and E7 of human papilloma virus type 16 or type 18; the connexon is connected with a nucleotide sequence for coding the human papilloma virus early regulatory protein E6 and a nucleotide sequence for coding the human papilloma virus early regulatory protein E7.

This invention provides a non-classical crRNA, reagent, kit, and application for one-step RPA-Cas12a nucleic acid detection. Based on classic crRNA, the non-classical crRNA shortens the 5' end by two bases and / or adjusts the stem-loop base structure to one of UCUUUU, UCUUU, UGUUU, UGUU, or UAAGU. This non-classical crRNA structure reduces the affinity of the Cas12a-crRNA complex for the target DNA, weakens the cis-cleavage activity of Cas12a, and increases the trans-cleavage activity of Cas12a, without requiring additional base modifications. This invention achieves a detection limit of 1 fM in the detection of Group B Streptococcus and Human Papillomavirus 16, with a sensitivity approximately 10-fold higher than before optimization.

The invention discloses a bigeminy immunoassay kit for detecting an HPV (human papillomavirus) antibody and a preparation method of the bigeminy immunoassay kit, relates to the field of biomedicine, and is characterized in that the bigeminy immunoassay kit for detecting the HPV antibody and the preparation method of the bigeminy immunoassay kit are provided. The magnetic microspheres for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 are coated with an HPV16 antibody and an HPV18 antigen, acridinium ester is used for marking the HPV16 antigen and the HPV18 antibody, an in-vitro diagnostic kit for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 is established on the basis, and a chemiluminescence immunoassay method is combined for analysis. The bigeminy immunoassay kit for quantitative detection of the HPV antibody is high in sensitivity, good in specificity, simple and convenient to operate and appropriate in price.

The invention relates to the field of biological medicine, in particular to mRNA designed for human papilloma viruses 16 and 18, a composition, a vaccine preparation and application of the mRNA. The mRNA, the composition and the vaccine preparation can induce potent and long-acting cellular immune response, can induce protective T cell memory, and can resist secondary attack and relapse of viruses; in addition, the growth rate of human papilloma virus positive tumors can be slowed down or regression of the human papilloma virus positive tumors can be mediated. The mRNA, the composition and the vaccine preparation provided by the invention can provide new technical means for treating infection of human papilloma virus type 16, positive cancer or precancerous lesion of the human papilloma virus type 16, infection of human papilloma virus type 18 and positive cancer or precancerous lesion of the human papilloma virus type 18.

This invention provides a mutant human papillomavirus (HPV) type 16 E2 protein and its application. The mutant E2 protein is obtained by the following three mutations based on the wild-type HPV type 16 E2 protein: (1) the serine at position 317 of the wild-type HPV type 16 E2 protein is mutated to proline; (2) the threonine at position 17 of the wild-type HPV type 16 E2 protein is mutated to arginine, and the asparagine at position 55 is mutated to arginine; (3) the histidine at position 218 of the wild-type HPV type 16 E2 protein is mutated to proline. This invention obtains the target protein through amino acid mutation and codon optimization, resulting in a more stable protein structure that is more conducive to expression, thereby significantly improving the yield and preparation efficiency of the HPV type 16 E2 protein. This antigen can be used for the detection of HPV type 16 E2 antibodies or to evaluate the humoral immunogenicity of therapeutic vaccines targeting HPV type 16 E2.

Disclosed are methods of selectively expanding a number of T cells each having antigenic specificity for a human papillomavirus (HPV) 6 or 11 antigen expressed by a tissue of a mammal. Also disclosed are methods of preparing a T cell product from an HPV 6 or 11 antigen positive papilloma from a mammal. Methods of treating or preventing a condition caused by a chronic HPV 6 or 11 infection in a mammal are also disclosed.

Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and / or treating infection with human papillomavirus type 6 and / or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof.[In the formula, R1, R2, p, L1 and L2 are as defined in the specification.]

The invention relates to polynucleotide for expressing HPV (human papilloma virus) 18 type main capsid protein L1 and application of the polynucleotide, and particularly discloses an optimized coding gene for coding the HPV 18 type main capsid protein L1. The gene is a sequence with at least 90% of identity of a polynucleotide sequence as shown in SEQ ID NO.1, the gene can efficiently express the main capsid protein L1 of the recombinant human papilloma virus type 18 after being transferred into pichia pastoris cells.

This invention discloses a germplasm screening and identification kit for anthracnose-resistant Camellia oleifera and its application, belonging to the technical field of germplasm screening and identification of anthracnose resistance genes in Camellia oleifera. Based on eight anthracnose resistance genes in Camellia oleifera, this invention develops a germplasm screening and identification kit for anthracnose-resistant Camellia oleifera. This invention enables rapid and efficient identification of anthracnose-resistant Camellia oleifera germplasm and can be used for high-throughput screening of anthracnose-resistant Camellia oleifera lines, providing a new method for disease-resistant breeding of Camellia oleifera.

The invention relates to the field of therapeutic nucleic acid vaccines, and discloses a design strategy of a therapeutic mRNA vaccine applicable to various human papilloma virus (HPV) type infection related precancerous lesions and tumors. The mRNA sequentially encodes E6 and E7 antigens from the N terminal to the C terminal, wherein the E6 and E7 antigens comprise a membrane-directed peptide and HPV de-carcinogenic antigens, and the E6 and E7 antigens can be directly connected or connected through a flexible joint of 1-20 amino acids. The mRNA can be delivered by various delivery systems, and the vaccine induces potent and lasting cellular immunity and humoral immunity in a mouse model; the strategy is suitable for treatment of high-grade squamous intraepithelial lesions and malignant tumors at the positions of cervix uteri, vagina, anus and the like caused by various HPV high-risk infections.